Post-earnings recap
Reported
Thu, May 9, 2024
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arrowhead Pharmaceuticals reported a significant loss per share, missing expectations dramatically. The stock reacted by declining nearly 2% in response to these disappointing results. Investors will need to wait for further details from management to understand the company's future direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.02 | N/A | -1545.16% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.